PASSAGE BIO, INC. Deferred Income Tax Liabilities, Net
PASSAGE BIO, INC. (PASG) had Deferred Income Tax Liabilities, Net of $3.04 million as of 2025-12-31, per its S-4/A filed 2026-09-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-09-03
- 2025-12-31: Deferred Income Tax Liabilities, Net $3.04M.
- 2024-12-31: Deferred Income Tax Liabilities, Net $4.45M.
- 2023-12-31: Deferred Income Tax Liabilities, Net $5.83M.
- 2022-12-31: Deferred Income Tax Liabilities, Net $8.42M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2025-12-31 | $3.04M S-4/A · filed 2026-09-03 |
| 2024-12-31 | $4.45M S-4/A · filed 2026-09-03 |
| 2023-12-31 | $5.83M 10-K · filed 2025-03-04 |
| 2022-12-31 | $8.42M 10-K · filed 2024-03-04 |
| 2021-12-31 | $1.22M 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |